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Abstract
Epstein–Barr virus (EBV) persists for the life of the host by accessing the long-lived memory B cell pool. It has been proposed that EBV uses
different combinations of viral proteins, known as latency types, to drive infected B cells to make the transition from resting B cells to memory
cells. This process is normally antigen-driven. A major unresolved question is what factors coordinate expression of EBV latency proteins. We
have recently described novel type III latency EBV+ B cell lines (OCI-BCLs) that were induced to differentiate into late plasmablasts/early plasma
cells in culture with interleukin-21 (IL-21), mimicking normal B cell development. The objective of this study was to determine whether IL-21-
mediated signals also regulate the expression of key EBV latent proteins during this window of development. Here we show that IL-21-reduced
gene and protein expression of growth-transforming EBV nuclear antigen 2 (EBNA2) in OCI-BCLs. By contrast, the expression of CD40-like,
latent membrane protein 1 (LMP1) strongly increased in these cells suggesting an EBNA2-independent mode of regulation. Same results were
also observed in Burkitt's lymphoma line Jijoye and B95-8 transformed lymphoblastoid cell lines. The effect of IL-21 on EBNA2 and LMP1
expression was attenuated by a pharmacological JAK inhibitor indicating involvement of JAK/STAT signalling in this process. Our study also
shows that IL-21 induced transcription of ebna1 from the viral Q promoter (Qp).
© 2007 Elsevier Inc. All rights reserved.Keywords: IL-21; B cell; EBV; EBV nuclear antigen 2; Latent membrane protein 1; Signal transducer and activator of transcriptionIntroduction
The secret to lifelong, persistent infection of human herpes-
virus, EBV, lies in its ability to access the long-lived memory B
cell pool. Restricted expression of viral proteins in memory
cells makes EBV invisible to the immune system. Also, in the
absence of viral proteins, these cells are not pathogenic and do
not present any threat to the host (Laichalk et al., 2002; Thorley-
Lawson, 2001).
RT-PCR data from tonsillar EBV+ B cells from healthy,
seropositive donors showed that the B cells from different
stages of development expressed distinct patterns of EBV
genes, also known as latency types (Babcock et al., 2000). This⁎ Corresponding author. Division of Stem Cell and Developmental Biology,
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doi:10.1016/j.virol.2007.12.027led to a model of viral latency in vivo where EBV uses its
arsenal of different latency types to increase the chances of
driving infected B cells past the developmental checkpoints to
reach the memory pool. According to this model, initial
infection of naive B cells results in proliferation induced by
six EBV-encoded nuclear antigens (EBNA1 to 6) and three viral
latent membrane proteins (LMP1, -2A, and -2B). This is known
as the growth program or type III latency and is thought to be
necessary for the establishment of infection in a large number of
B cells. The next stage of differentiation is characterized by the
type II latency pattern also called the default program. Here
EBV+ B cell blasts decrease expression of EBNA2 but maintain
expression of LMP1 and LMP2A proteins that provides signals
that mimic those provided by CD40 and the BCR, respectively
(Caldwell et al., 1998; Uchida et al., 1999). At the next stage of
development, EBV+ B cells differentiate into memory cells as
they lose expression of LMP1 and LMP2A. EBNA1 is the only
viral protein detectable in circulating peripheral blood memory
B cells where it plays a role in the maintenance of the viral
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or type I latency (Babcock et al., 2000; Thorley-Lawson, 2005).
EBV-associated B cell malignancies can be classified based
on the type of viral latency. For instance, Burkitt's lymphoma
cells and some B cell lines established in vitro express type I
latency of infection. Hodgkin's disease (HD) B cells express
type II latency. Non-Hodgkin's lesions such as posttransplant
lymphoproliferative disorder (PTLD) and AIDS-associated
lymphomas, mostly display type III viral latency. B cells
transformed by EBV into lymphoblastoid cell lines (EBV+
LCLs) in vitro also express type III latency (Thorley-Lawson,
2001; Young and Rickinson, 2004). Therefore, characterization
of signals that regulate transitions between different types of
viral latency during EBV+ B cell development in a healthy host,
would also provide important insights into the mechanisms of
initiation and maintenance of EBV-associated malignancies.
In the course of Ag-activation and differentiation in the GC
follicles or in the extrafollicular areas of tonsils or lymph nodes,
newly-infected naive B cells or latently-infected memory B cells
would likely be exposed to the same lymphoid microenviron-
ment-derived signals as are normal, Ag-activated B cells. These
signals could also control EBV life cycle by modifying the
expression patterns of EBV latency and lytic genes in infected B
cells. CD4+ Th-mediated signals, like CD40L and cytokines, are
the obvious candidates in this process since Ag-activated B cells
are found in close contacts with CD4+ Th cells during T cell-
dependent Ag responses. CD4+ Th cells provide essential cog-
nate help for class switching, and contribute to B cell decisions to
differentiate into memory or PCs following Ag stimulation
(McHeyzer-Williams and McHeyzer-Williams, 2005; Vinuesa
et al., 2005).
Only a few studies have examined the role of Th-derived
signals in regulation of EBV protein expression in B cells with
type III latency. One study showed that CD40 ligation decreased
both EBNA2 and LMP1 expression in five EBV+ LCLs in vitro
(Pokrovskaja et al., 2002). Another report showed that exposure
to IL-6 reduced expression of both EBNA2 and LMP1 in
parallel with the induction of cell-cycle arrest, Ig secretion, and
apoptosis in two EBV+ LCLs (Altmeyer et al., 1997). In the
case of B cells with more restricted types of viral latency (type
II), it was shown that CD40L and IL-4 increased LMP1 levels in
EBNA2-negative KMH2 Hodgkin's lymphoma line (Kis et al.,
2005a). IL-10 was also shown to induce LMP1 in EBNA2-
deleted EBV+ BL lines Daudi and P3HsR1, in the conditional
LCL, ER/EREB-5, when EBNA2 expression was turned off,
and in normal B cells when infected in vitro with the EBNA2-
deleted P3HR1 EBV strain (Kis et al., 2005b; Kis et al., 2006).
Similarly, two EBV+ NK cell lines responded to IL-10 by
increasing expression of LMP1 (Takahara et al., 2006).
IL-21 is a recently identified common γ chain receptor-
dependent cytokine (Nutt et al., 2004; Parrish-Novak et al., 2000,
2002) that is secreted by follicular B helper Tcells and by activated
CD4+ Th cells (Chtanova et al., 2004; Kuchen et al., 2007;
Leonard and Spolski, 2005; Mehta et al., 2005; Nutt et al., 2004).
Upon maturation, both human and murine peripheral B cells
express high levels of IL-21 receptor α (IL-21R) that are further
increased during B cell activation (Good et al., 2006; Jin et al.,2004). CD4+ Th subset mediated secretion of IL-21 is indicative
of its function as a mediator of Tcell signals to IL-21R-expressing
activatedB cells that pass through the secondary lymphoid tissues.
It has been shown that IL-21 induced differentiation of human
naive B cells, post-switch memory B cells, and cord blood B cells
into Ab-producing PCs in vitro after they were activated by
crosslinking of their BCR and CD40 receptors (Ettinger et al.,
2005; Good et al., 2006). IL-21 strongly augmented proliferation
of CD40 ligand-stimulated human neonatal, splenic naive and
memory, and tonsil GC B cells which exceeded that induced
by cytokines known to regulate B cell proliferation such as IL-4,
IL-10, and IL-13 (Good et al., 2006). The effects of costimulation
by IL-21 on murine and human B cells can be variable, so that the
final outcomes of its signalling seem to depend on the activation
state, or on the developmental stage of the target cells. IL-21 was a
potent growth factor of multiple myeloma cells, while it initiated
apoptosis in chronic lymphocytic leukemia B cells (Brenne et al.,
2002; de Totero et al., 2006).
We have established type III latency EBV+ human B cell lines
(OCI-BCLs) that resemble post-GC, Ag-activated IgG+ B cell
blasts as determined by their transcription factor status and cell
surface protein expression (Konforte and Paige, 2006).As recently
reported, these cells were successfully used as an in vitro model
system to track cellular intermediates andmolecular pathways that
constitute the IL-21-mediated transition from an activated B cell to
an Ig-secreting B cell. We demonstrated that exposure to IL-21
enhanced the proliferation of OCI-BCLs followed by their
differentiation into late plasmablasts/early PCs (Konforte and
Paige, 2006). Considering the important role of IL-21 in human B
cell development, and the proposed association between EBV life
cycle and B cell development, we wanted to determine whether
IL-21-mediated signals could regulate the expression of EBV
latency proteins in differentiating EBV+ B cells.
In this paper we demonstrate, for the first time, that IL-21-
induced differentiation of OCI-BCLs into Ig-secreting late
plasmablasts/early PCs is associated with striking changes in the
expression of key EBVoncoproteins EBNA2 and LMP1, known
for their important roles in growth and survival of infected B
cells. Addition of IL-21 to the cultures of OCI-BCLs caused a
strong reduction in EBNA2 protein levels. This change was
preceded by an increase in LMP1 protein expression. Same
pattern of regulation was observed in other EBV-infected B
cells, including Burkitt's lymphoma and B95-8-infected lym-
phoblastoid cell lines. Here, we also provide evidence for the
contribution of IL-21-induced JAK/STAT signalling pathway in
the regulation of EBNA2 and LMP1. In addition, we show that
IL-21 increases transcription of ebna1 from the Q promoter (Qp)
in EBV+ B cells.
Results
IL-21 reduces expression of EBNA2 protein in OCI-BCLs and
in blood- and tonsil-derived human B LCLs that were in vitro
transformed with B95-8 strain of EBV
As previously reported, we cloned B cell lines from B cell
populations that were established from in vitro cultures of
Table 1
Quantitation of EBNA2+ cells in control and IL-21-containing wells on day 6 of
culture
Average number of EBNA2+ cells per 100 cells
Control +IL-21 (50 ng/ml)
OCI-BCL1 47±6 20±3
OCI-BCL2 66±5 20±2
OCI-BCL3 59±6 36±2
OCI-BCL5 52±4 30±3
Photographs of cells from each cytospin slide were taken from three, non-
overlapping fields of view. At least 300 cells were counted per slide. Scoring is
expressed as a number EBNA2+ cells per 100 total cells counted. Displayed
numbers represent mean±SE calculated over two experiments for each line.
102 D. Konforte et al. / Virology 374 (2008) 100–113synovial cells obtained from four arthritis patients (Konforte
and Paige, 2006). All cell lines were positive for EBV. RT-PCR
and immunostaining results indicated that these cells expressed
EBV nuclear antigens, EBNA2 and EBNA3C, and latent
membrane proteins, LMP1 and LMP2A (data not shown). This
profile of viral gene expression is typical of type III viral latency
(Young and Rickinson, 2004).
To test whether IL-21 plays a role in regulation of EBV latent
cycle, we analyzed the expression pattern of the growth-trans-
forming, type III latency specific protein, EBNA2, in OCI-BCLs
that were cultured with IL-21 for 6 days. Western blot analysis of
the nuclear lysates revealed that the earliest decrease in EBNA2
expression was observed 48 h after addition of IL-21 to the cell
cultures (Fig. 1A). Nuclear c-Myc, whose expression is known to
be positively regulated by EBNA2, also decreased after 48 h of
culture with IL-21 (Fig. 1A). Low levels of EBNA2 protein were
sustained on day 3 and on day 6 of culture (Fig. 1A and B).
Based on the immunostaining with EBNA2-specific antibody,
we calculated that, on average, between 47% and 66% of cells,Fig. 1. IL-21 decreases expression of EBNA2 in EBV+ B cell lines. (A)Western blot a
BCL3 0', 40', 6 h, 24 h, 48 h, and 72 h after addition of IL-21 to the culture. EBV+ LC
negative controls, respectively, for detection of EBNA2 protein. (B) Western blot ana
and -BCL5 cells from day 3 and 6 of culture with IL-21. Actin demonstrates equal pro
BCL1 and OCI-BCL3 cells from day 6 of culture were fixed and stained with anti-
analysis of IL-21-induced changes in EBNA2 expression in nuclear lysates from bloo
B95-8 strain of EBV. Actin demonstrates equal protein loading.depending on the cell line, were positive for EBNA2 at steady
state (Fig. 1C, Table 1). Similarly to the previous reports, we
observed that EBNA2 intensity in each cell line varied con-
siderably between individual positive cells (Pokrovskaja et al.,
2002). In line with the Western blot results, immunostaining datanalysis of changes in EBNA2 and c-Myc expression in nuclear lysates from OCI-
L-BRC, and EBV− B cell lines OCI-Ly7 and OCI-My2 were used as positive and
lysis of EBNA2 expression in nuclear lysates from OCI-BCL1, -BCL2, -BCL3,
tein loading in both (A) and (B). (C) Cytospins of control and IL-21-treated OCI-
EBNA2 Ab. Cell images were acquired at 20× magnification. (D) Western blot
d-derived (BRC) and tonsil-derived (2D5) LCLs that were in vitro infected with
103D. Konforte et al. / Virology 374 (2008) 100–113revealed a consistent reduction in the numbers of EBNA2+
cells in four OCI-BCLs on day 6 of culture with IL-21 (Fig. 1C,
Table 1).
To determine whether IL-21-mediated regulation of EBNA2
protein levels has relevance beyond the confines of OCI-BCLs,
we tested its effects on different types of EBV-infected B
lymphoblastoid cell lines (LCLs). Western blot results from day
3 and day 6 indicate that the tonsil-and blood-derived LCLs
(2D5 and BRC) that were in vitro infected with EBV lab strain
B95-8 also decreased EBNA2 expression in culture with IL-21
(Fig. 1D).
IL-21-treatment of EBV+ B cell lines reduces expression of the
Cp-initiated transcripts, decreases expression of lmp2a
message, and increases expression of lmp1 message
Expression of EBV genes that constitute different types of
viral latency is controlled by differential utilization of viral
promoters. In type III latency, all ebna genes, including ebna2,
are transcribed from polycistronic mRNA originating from the
C promoter (Cp) (Sung et al., 1991; Tierney et al., 1994).
EBNA2 is essential for transactivation of the Cp (Sung et al.,
1991). To determine whether IL-21-induced decrease in EBNA2
protein levels paralleled changes in the Cp activity, we analyzed
the expression of transcripts initiated from the Cp. RT-PCR
analysis of gene expression between day 0 and day 3, showed
that the Cp-initiated transcripts decreased in OCI-BCLs in re-
sponse to IL-21 in a time-dependent fashion (Fig. 2). In addition,Fig. 2. Regulation of expression of the Cp-initiated transcripts, and of lmp1 and
lmp2a transcripts by IL-21. RT-PCR analysis of the Cp-driven transcripts, of
the Cp-driven ebna1 transcripts, and of ebna2, lmp2a, and lmp1 transcripts in
OCI-BCL1 0 h, 6 h, 24 h, 48 h, and 72 h after addition of IL-21 to the culture.
OCI-BCL1 is representative of three OCI-BCLs that were tested. C1/C2-W2 and
Y3-U-K denote exons of EBV genome spanned by the primers used to amplify
Cp-long transcript and ebna1 (Cp-driven) transcripts, respectively. Primers used
in lmp1 PCR amplify messages expressed from both ED-L1 and L1-TR
promoters. For RT-PCR analysis, serial dilutions of control and IL-21-treated
OCI-BCL1 cDNA (1:1, 1:2, 1:5, 1:10, 1:50) were used to amplify sequences of
each of the above-mentioned genes (data not shown). Quantitated intensity of
PCR bands amplified from each dilution fell within the linear range of
amplification process. cDNA dilutions of 1:2 were used in all subsequent PCR
reactions. All expression values were quantitated by NIH Image 1.61 software
according to the manufacturer's instructions and normalized to a housekeeping
gene actin. Displayed numbers represent fold change in normalized gene
expression relative to expression in control (0 h) samples.the time-course analysis revealed that the splice products of the
Cp-initiated transcript, such as ebna1 and ebna2, decreased in
response to IL-21 (Fig. 2).
Apart from regulating the Cp, EBNA2 has been shown to be
the major transactivator of the lmp2a and lmp1 promoters in
type III latency of infection (Johannsen et al., 1995; Laux et al.,
1994). RT-PCR data showed that lmp2a gene expression de-
creased, while lmp1 gene expression increased in OCI-BCLs
cultured with IL-21. Reduction in lmp2a message could,
therefore reflect the decrease in EBNA2 expression (Fig. 2).
Surprisingly, we observed an increase in lmp1 message 6 h after
addition of IL-21 to the cell cultures. Augmented levels of lmp1
message were sustained even after 3 days of culture with IL-21
(Fig. 2).
IL-21 increases expression of LMP1 protein in OCI-BCLs,
in blood- and tonsil-derived B cell lines in vitro transformed
with B95-8 strain of EBV, and in Burkitt's lymphoma B cell
line Jijoye
Western blot analysis revealed a strong increase in LMP1
protein levels in OCI-BCLs cultured with IL-21. In agreement
with the RT-PCR data (Fig. 2), the initial increase was detected
as early as 6 h after addition of IL-21 to the culture (Fig. 3A).
Augmented expression of LMP1 was maintained throughout the
culture with IL-21 (Fig. 3B). This trend applied to all OCI-
BCLs. Immunostaining with LMP1-specific antibody con-
firmed Western blot results (Fig. 3C).
To determine whether an increase in LMP1 protein expres-
sion in response to IL-21 is a general feature of EBV-infected B
cells, we tested different types of EBV-infected B cell lines.
Western blot results indicate that the blood- and tonsil-derived
LCLs (BRC and 2D5) that were in vitro infected with EBV lab
strain B95-8 also showed strong increase in LMP1 expression in
response to IL-21 (Fig. 3D). OCI-BCL1 was used as a positive
control. In addition, a Burkitt's lymphoma B cell line, Jijoye,
infected with the type B EBV, increased LMP1 expression in
culture with IL-21 (Fig. 3D).
IL-21-induced STATs bind to the sequences in both ED-L1 and
L1-TR LMP1 promoters
LMP1 transcription can be initiated from two promoters in
the EBV genome, a proximal promoter referred to as the ED-L1
promoter, and a distal promoter named L1-TR. The L1-TR
promoter is located within the viral terminal repeats, approxi-
mately 600 bp upstream of ED-L1 (Chang et al., 1997; Sadler
and Raab-Traub, 1995). Primers used in our RT-PCR experi-
ments amplify transcripts originating from both ED-L1 and L1-
TR (Fig. 2). In latency type III, LMP1 expression is typically
mediated by EBNA2-dependent activation of ED-L1, while in
latency II, LMP1 expression can be driven by both the L1-TR
and the ED-L1 promoters (Abbot et al., 1990; Sadler and Raab-
Traub, 1995; Sjoblom et al., 1995a,b; Wang et al., 1990). LMP1
protein translated from both transcripts is the same, since
both transcripts use the same ATG (Chen et al., 2001). We used
RT-PCR combined with Southern blotting to determine whether
Fig. 3. IL-21 increases expression of LMP1 protein in EBV+ B cell lines. (A) Western blot analysis of changes in LMP1 expression in OCI-BCL3 0', 40', 6 h, 24 h,
48 h, and 72 h after addition of IL-21 to the culture. EBV+ LCL-BRC, and EBV− B cell lines OCI-Ly7 and OCI-My2 represent positive and negative controls,
respectively, for detection of LMP1 protein. (B) Western blot analysis of LMP1 expression in OCI-BCL1, -BCL3, and -BCL5 cells from day 3 and 6 of culture with
IL-21. Actin demonstrates equal protein loading in both (A) and (B). (C) Cytospins of control and IL-21-treated OCI-BCL1 and OCI-BCL3 cells from day 6 of culture
were fixed and stained with anti-LMP1 Ab. Cell images were acquired at 20× magnification. (D) Western blot analysis of IL-21-induced changes in LMP1 expression
in lysates from LCL-BRC, LCL-2D5, and Burkitt's lymphoma B cell line, Jijoye.
104 D. Konforte et al. / Virology 374 (2008) 100–113IL-21 affected the transcription from the L1-TR promoter in
OCI-BCLs, LCLs, and in Jijoye. As previously described, RT-
PCR was performed using primers which specifically detect
749-bp product initiated from the L1-TR. The larger product
(903 bp) is amplified from EBV genomic DNA (Chen et al.,
2001) since it can also be detected in samples that contained no
reverse transcriptase (no RT) as shown for 2D5 LCL line. No
RT samples lacked 749-bp product that represents sequences in
the L1-TR-initiated message (Fig. 4). OCI-Ly19, an EBV− B
cell line, was used as a negative control. Time-course analysis
shows that IL-21 increased transcription from the L1-TR
promoter in OCI-BCL1 and in Jijoye cells (Fig. 4). In 2D5, an
increase in L1-TR-initiated transcripts was the greatest at 48 h,
and decreased by day 4. However, the expression on day 4 was
still above that observed in the control cells on day 0 (Fig. 4). In
the case of 2D5, L1-TR transcripts were expressed in sufficient
quantities to be detected by RT-PCR alone. We did not detect
any L1-TR-initiated transcripts in IL-21-treated OCI-BCL2,
suggesting that lmp1 gene is transcribed exclusively from the
ED-L1 promoter in this cell line (data not shown).
To gain some insight into the mechanism of regulation of
ED-L1 and L1-TR promoters in IL-21-treated EBV+ B cells, weperformed mobility shift assays (EMSA). First, we tested
whether IL-21 could induce binding of STATs (signal trans-
ducers and activators of transcription) to the STAT binding sites
that were previously identified in ED-L1 and L1-TR promoter
sequences (Chen et al., 2001). Mobility shift assays were done
using 32P-labelled double-stranded oligo probes containing ED-
L1 and L1-TR sequences. Protein lysates were quantitated prior
to EMSAs and equal amount of nuclear lysates from both the
control and the IL-21-treated cells was used in the assay. This
was additionally confirmed by Western blot analysis of nuclear
actin levels (Fig. 5A). Binding to human serum-inducible ele-
ment (hSIE) DNA probe was used as a positive control to
determine whether IL-21 stimulation augmented nuclear bind-
ing of STAT molecules in EBV+ B cell lines. hSIE is derived
from the IFN-γ-activated site (GAS) in the c-fos promoter,
which is a common DNA sequence for STAT protein binding.
Specifically, the triplet of bands showing the association of
STAT1 homodimers, STAT3 homodimers, and STAT1:STAT3
heterodimers can be visualized using this probe (Srivastava et al.,
2004; Vougier et al., 2007). In OCI-BCL1 lysates stimulated with
IL-21 for 24 h, there was a robust increase in the association
between STAT1 homodimers, STAT1:3 heterodimers, and STAT3
Fig. 4. IL-21 increases transcription of lmp1 from the L1-TR promoter in EBV+ B cell lines. RT-PCR analysis of the L1-TR-driven transcripts in OCI-BCL1, Jijoye,
and LCL-2D5 cells 0', 6 h, 24 h, 48 h, and 72 h after addition of IL-21 to the culture. OCI-BCL1 is representative of three OCI-BCLs that were tested. 32P-labelled
probe that specifically binds to the L1-TR-induced lmp1 message was used in the Southern blot. In LCL-2D5, RT-PCR products were abundant enough to detect
without subsequent Southern blotting. OCI-Ly19 cells were used as a negative control. Top RT-PCR band (903 bp) was amplified from EBV plasmid DNA, while
lower band (749 bp) was amplified from cDNA. Actin was used as a housekeeping gene. No RT = Reverse transcriptase (RT) was not added to two LCL-2D5 samples
to confirm that the 903 bp band represents EBV plasmid DNA.
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of STAT binding, anti-STAT1 and anti-STAT3 antibodies (Ab)
were added to some binding reactions. Addition of anti-STAT3
Ab resulted in appearance of a shifted complex (ss-supershift).
While anti-STAT3Abmainly targeted STAT1:3 heterodimers and
STAT3 homodimers, it also recognized STAT1 homodimers.
Addition of anti-STAT1 Ab strongly reduced binding of STAT1
homodimers to the hSIE probe, but no shifted complex was
evident (Fig. 5A). This is in agreement with the previous reports
which showed that the same anti-STAT1 Ab prevents binding of
STAT1 complexes to DNA without formation of a shifted
complex. (Asao et al., 2001; Dumler et al., 1999; Ziros et al.,
2004).Our results also show that anti-STAT1Abpartially reduced
binding of STAT1:3 heterodimers and STAT3 homodimers to
hSIE probe.
In addition, we used a pharmacological inhibitor of JAK
kinase activity, JAKi I, to confirm that the protein complexes
that bound to the hSIE probes were indeed STATs. Thompson et
al. used in vitro kinase assays to show that nanomolar levels
JAKi I specifically inhibited kinase activity of JAKs (Thomp-
son et al., 2002). We have previously shown that Jaki I alone
does not affect either growth or survival of the control OCI-
BCLs at concentrations lower than 250 nM (Konforte and
Paige, 2006). EMSA results clearly show that IL-21-induced
STAT binding to hSIE is severely reduced in the presence of
JAKi I (Fig. 5A).
EMSAs also revealed that IL-21 induced binding of STAT-
containing complexes to ED-L1 and L1-TR probes (Fig. 5B and
C). This was clearly confirmed by the addition of anti-STAT1 or
anti-STAT3 Abs to the binding reactions, or with Jaki I. Anti-
STAT1 Ab decreased binding of STAT complexes to ED-L1
sequences, while addition of anti-STAT3Ab resulted in decreased
binding and in a supershifted complex. This result strongly sug-
gests that both STAT1 and STAT3-containing complexes couldcontribute to regulation of ED-L1 promoter in EBV+ B cells
(Fig. 5B).
Anti-STAT1 Ab did not decrease binding of STAT com-
plexes to L1-TR sequences, while anti-STAT3 Ab resulted in a
strong shifted complex (Fig. 5C). This suggests that STAT3-
containing complexes likely bind to the L1-TR sequences. This
result is in agreement with the previous report where STAT3
was proposed to be the relevant STAT in regulation of L1-TR in
EBV+ epithelial cells (Chen et al., 2003, 2001). Similar to
results shown by Chen et al. (2001), IL-21-induced STAT
binding was not evident when mutations were introduced in the
putative STAT binding sites in the L1-TR sequences (L1-TRmt)
(Fig. 5C). 32P-dATP labelling of both L1-TR and L1-TRmt was
equal with 40,000 cpm used per reaction (data not shown).
Furthermore, pretreatment of cells with 200 nM of Jaki I
strongly opposed IL-21-mediated increase in binding of STATs
to both the ED-L1 and L1-TR probes (Fig. 5B and C). As an
additional test of specificity of STAT binding, STAT complexes
were competed away by excess unlabelled hSIE (Fig. 5A) and
ED-L1 or L1-TR probes (Fig. 5B and C).
Collectively, results presented in Figs. 4 and 5 suggest that
the transcription from both LMP1 promoters likely contributes
to the overall increase in the expression of LMP1 transcripts in
response to IL-21. In addition, the results shown in Fig. 5B and
C represent the first evidence for STAT binding to LMP1
promoter sequences using cytokine-induced EBV+ B cell
lysates instead of purified STATs.
IL-21-induced JAK/STAT signalling contributes to the
regulation of expression of EBNA2 and LMP1 in EBV+ B
cell lines
We have previously shown that JAK1, JAK3, STAT1, and
STAT3 molecules were activated minutes after addition of IL-21
Fig. 5. Increased associations between IL-21-activated STATs and the ED-L1 and L1-TR promoters. (A, B, and C) EMSA showing binding of STATs from the control
and IL-21-stimulated nuclear lysates to 32P-labelled double-stranded hSIE probes and 32P-labelled double-stranded probes containing STAT sites from the ED-L1 and
L1-TR promoters. Nuclear lysates were obtained from OCI-BCL1 cells cultured with IL-21 for 24 h. Anti-STAT1 Ab, anti-STAT3 Ab, and 200 nM of pharmacological
inhibitor of JAK kinase, JAKi I, were used to test the specificity of STAT binding to the probes. In Fig. 5A, the results of Western blot for nuclear actin expression were
shown for control, IL-21-treated, and IL-21+Jaki-treated samples. L1-TRmt = 32P-labelled double-stranded L1-TR probe with mutations in the putative STAT
sequences. 1:1 = STAT1 homodimers, 1:3 = STAT1:STAT3 heterodimers, 3:3 = STAT3 homodimers, SS = supershifted complex, NS = non-specific binding, cc = cold
competition with excess unlabelled probes. OCI-BCL1 is representative of other two OCI-BCLs and LCL-2D5 that were tested by EMSA.
106 D. Konforte et al. / Virology 374 (2008) 100–113to the cultures of OCI-BCLs (Konforte and Paige, 2006).We have
also shown that intact JAK/STAT signalling was required for IL-
21-mediated differentiation of OCI-BCLs into late plasmablasts/
early PCs in vitro (Konforte and Paige, 2006). Here we tested the
contribution of JAK/STAT pathway in IL-21-induced regulation
of EBNA2 and LMP1 protein expression in OCI-BCLs. Western
blot analysis of the nuclear lysates from day 3 and day 6 of culture
showed that IL-21-induced repression of EBNA2 was stronglyopposed in the presence of JAKi I (Fig. 6A). Notably, a decrease
in c-Myc expression was also opposed by the JAKi I (Fig. 6A). In
addition, JAK/STAT signalling pathway contributed to IL-21-
mediated regulation of LMP1 since JAKi I partially prevented an
increase in LMP1 levels (Fig. 6B). This finding together with the
results from the mobility shift assays (Fig. 5B and C) strongly
suggests that IL-21-induced JAK/STATsignalling pathway is one
of the major regulators of LMP1 expression in EBV+ B cells.
Fig. 6. Contribution of JAK/STATsignalling to IL-21-mediated regulation of the
EBNA2 and LMP1 in EBV+ B cell lines. OCI-BCL1 and OCI-BCL3 were
incubated with 200 nM of JAKi I for 45 min at 37 °C prior to addition of IL-21
(50 ng/ml) to the cultures. Cell lysates were collected at indicated times after
addition of IL-21 to the culture. (A) EBNA2, c-Myc, and (B) LMP1 were
detected by Western blotting. All expression values were quantitated by NIH
Image 1.61 software according to the manufacturer's instructions and normal-
ized to a housekeeping gene actin. Displayed numbers represent fold change in
normalized protein expression relative to expression in control samples.
Comparisons were performed between the samples obtained on the same day
of culture. OCI-BCL1 and OCI-BCL3 are representatives of other two OCI-
BCLs and LCL-2D5 that were tested by Western blot.
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EBV+ B cell lines
Activation of the Q promoter (Qp) is a hallmark of a shift
from type III to more restricted, type I/II viral latency (Thorley-
Lawson and Gross, 2004). During type I/II latency, Qp is used to
express EBNA1, which is essential for the maintenance of the
EBV genome in dividing cells (Lee et al., 1999; Nonkwelo et al.,
1996; Schaefer et al., 1995). It has been previously shown that
the Qp drives transcription of EBV genes in EBV-associated
tumours in nonimmunocompromised patients (Chen et al.,
1999). A major open question is what signals initiate transcrip-tion form the Qp in infected B cells. Here we tested whether IL-
21-mediated signals play a role in this process. Since the Qp
transcripts are known to be expressed at low levels in EBV-
transformed cell lines, we used RT-PCR in combination with the
Southern blot where 32P-labelled probe was designed to bind the
U exon within the Qp-driven ebna1 RT-PCR product (Q-U-K).
The results showed that IL-21 increased the Qp-initiated ebna1
transcripts in OCI-BCL cells in time-dependent fashion
(Fig. 7A). EBV+ Burkitt's lymphoma (BL) B cell line, Raji,
was used as a positive control for detection of the Qp-initiated
ebna1 transcription. EBV− B cell line OCI-Ly19 was used as a
negative control (Fig. 7A).
Identification of functional STAT binding sites in the Qp
sequences and promoter–reporter assays showed that the JAK/
STAT pathway positively regulated Qp activity in nasophar-
yngeal carcinoma (NPC) cell lines (Chen et al., 1999, 2001).
Reporter assays in HeLa cells co-transfected with the EBV
latency Qp-CAT constructs and a control vector, an expression
plasmid for v-Src, or v-Src plus a dominant negative STAT3
inhibitor (STAT3β) suggested that STAT3 is the biologically
relevant STAT for EBNA1 Qp promoter regulation (Chen et al.,
2001). We used EMSA to test whether IL-21 simulation
regulated binding of STATs to the Qp sequences. We observed
an increase in the association between the Qp probe and protein
complexes from OCI-BCL2 lysates stimulated with IL-21 for
24 h (Fig. 7B). However, neither anti-STAT1 nor anti-STAT3
Ab reduced binding or resulted in the formation of a shifted
band, suggesting that this protein complex does not contain
STATs. Furthermore, Jaki I did not significantly reduce IL-21-
mediated binding of the protein complex to the Qp probe. In
summary, we could not detect specific binding of STAT1- or
STAT3-containing complexes to the Qp sequences in IL-21-
treated EBV+ B cells.
Discussion
Results presented in this report represent important novel
findings that might help to understand how EBV genes can be
regulated by the signals from the microenvironment in vivo in a
manner that dominates over the intrinsic viral gene regulation
program imposed by EBNA2 in type III latency.
The main finding of our study is the dissociation of EBNA2
and LMP1 expression by IL-21-mediated signalling. We found
that EBNA2 expression progressively decreased, while LMP1
levels increased in IL-21-treated EBV+ B cells. Increased LMP1
expression was sustained even on day 6 of culture with IL-21,
while EBNA2 expression remained low compared to the con-
trols. Collectively, our data suggest that IL-21 regulates LMP1
expression in an EBNA2-independent fashion, a scenario that
has been previously reported only in EBV+ B cell lines with
type I and type II latency isolated from the Burkitt's lymphoma
or Hodgkin's lymphoma patients, and in EBV-positive
nasopharyngeal epithelial cell lines (Kis et al., 2006).
Our data also show that intact JAK/STAT pathway was
required for the IL-21-mediated regulation of EBNA2 and
LMP1 protein expression. Partial inhibition of IL-21-induced
tyrosine phosphorylation of STAT1 and STAT3 by the JAKi I
Fig. 7. IL-21 induces ebna1 transcription from the Qp in EBV+ B cell lines. (A) RT-PCR analysis of the Qp-driven ebna1 transcripts in OCI-BCL2 and OCI-BCL5 cells
0, 6 h, 24 h, 48 h, 72 h, and 4 days after addition of IL-21 to the culture. Q-U-K denotes exons of EBV genome spanned by the primers used to amplify the Qp-driven
transcripts. 32P-labelled probe that binds to the U exon was used in the Southern blot to confirm the RT-PCR results for the Qp-driven ebna1 transcripts. EBV+ B cell
line Raji represents a positive control, and EBV− B cell line OCI-Ly7 represents a negative control for detection of the Qp-driven ebna1. (B) EMSA to test binding
of STATs from the control and IL-21-stimulated nuclear lysates from OCI-BCL2 cells to 32P-labelled double-stranded Qp probes containing putative STAT sites.
cc = cold competition (unlabelled Qp probe). OCI-BCL2 is representative of other two OCI-BCLs and LCL-2D5 that were tested by EMSA.
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proteins.
In addition, our report shows that IL-21-mediated regulation
of EBNA2 and LMP1 has relevance beyond the confines of
OCI-BCLs. Identical effects observed in B95-8-infected blood-
and tonsil-derived B cell lines suggest that the IL-21-mediated
regulation of these key EBVoncoproteins is a general feature of
EBV+ B cell lines, regardless of the cellular background or viral
strains. Furthermore, LCL-2D5 B cells are surface IgM+λ+,
while LCL-BRC and all OCI-BCLs are surface IgG+κ+ (data
not shown) indicating that the observed response to IL-21 is not
restricted to a particular isotype of EBV-infected B cells.
EBNA2 contributes to cellular proliferation and survival of
EBV-infected B cells, most likely by its ability to act as a
transcriptional activator of cellular and viral gene expression. It is
a functional homologue of activated Notch receptor (Hayward,
2004; Hofelmayr et al., 2001). Similar to Notch, EBNA2 interacts
with the transcription factor RBP-Jκ. This interaction leads to
activation of the viral promoter, Cp, which regulates expression of
all EBV nuclear antigens (EBNAs), including EBNA2 itself, aswell as to activation of lmp1 and lmp2a promoters (Hayward,
2004; Zimber-Strobl and Strobl, 2001). In agreement with the
essential role of EBNA2 in the transactivation of these promoters,
we found that IL-21-mediated decrease in EBNA2 correlatedwith
a decrease in expression of the Cp-initiated transcripts and their
splice products, ebna1 and ebna2. Reduction of lmp2a message
also paralleled reduction in ebna2. However, the IL-21-induced
signals were not sufficient to completely inhibit the expression of
the Cp-initiated and the lmp2a-initiated transcripts. This suggests
that either EBNA2 expression has to be completely abolished or
that other factors, in addition to EBNA2, contribute to regulation
of transcription from these promoters.
Apart from regulation of viral genes, EBNA2 also drives
transcription of proliferation- and survival-associated cellular
genes such as CD21, CD23, c-fgr, and c-Myc (Cohen et al.,
1989; Cordier et al., 1990; Kaiser et al., 1999; Kempkes et al.,
1995; Wang et al., 1991; Zhao et al., 2006). This is consistent
with our results that showed that reduction in EBNA2 expression
coincided with a decrease in c-Myc expression in EBV+ B cells
lines cultured with IL-21. Furthermore, treatment with the Jaki I
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well as the decrease of c-Myc in EBV+ B cell lines. It has been
proposed that EBNA2 takes control over the cellular transcrip-
tional machinery in order to block B cell differentiation at the
proliferative stage by mimicking the Notch signalling pathway
(Ling et al., 1994; Polack et al., 1996). Results from this and our
previous report (Konforte and Paige, 2006) collectively suggest
that IL-21-induced signalling pathways can function to override
the inhibitory effect of EBNA2 which then allows infected B
cells to exit the cell-cycle and differentiate.
In the cytokine-rich environment in which EBV+ B cells
develop, LMP1 expression could persist despite the decrease in
EBNA2 levels. LMP1 oncoprotein acts as a viral mimic of CD40,
a cellular regulator of B cell proliferation and survival. Unlike
CD40 that positively affects proliferation only in the presence of
its ligand presented by activated T cells in the lymphoid tissues,
LMP1 acts constitutively, in a ligand independent fashion, to
maintain proliferation and survival of EBV-infected B cells
(Hatzivassiliou et al., 2007; Uchida et al., 1999). Cytokine-
mediated activation of LMP1 expression in the absence of
EBNA2 could provide developing EBV-infected B cells with
additional survival signals and thereby increase their chances of
successful differentiation in a highly competitive environment of
the lymphoid organs. Here, we show that increase in LMP1
protein expression occurred by 6 h after addition of IL-21 to the
cell culture. Furthermore, we show that IL-21-activated STAT1
and STAT3 could bind to the STATsites in the ED-L1 and L1-TR
promoters, suggesting a direct relationship between IL-21R-
mediated JAK/STAT signalling and regulation of LMP1 expres-
sion. This is in agreement with the previous results that showed
the requirement for JAK/STAT pathway in the regulation of the
LMP1 promoters in EBV+ epithelial cell lines (Chen et al., 2003,
1999, 2001).
L1-TR promoter was shown to be active in nasopharyngeal
carcinoma (NPC) cells that lack expression of EBNA2 (Chang
et al., 1997; Chen et al., 2001). Detection of L1-TR activity in
an EBV-positive B cell line treated with IL-6 and in a sample of
EBV-positive Hodgkin's disease tissue suggested that usage of
this promoter is not restricted to EBV+ tumours of epithelial
origin (Chen et al., 2001). Here we extend those findings by
showing that IL-21 induced transcription from the L1-TR in B
cells including OCI-BCLs, LCLs, and in Jijoye lines.
A switch from the type III to the type II/I viral latency in
infected B cells is characterized by the loss of EBNA2 expression
and by the increase in transcription from the promoter Qp.
Cytokine-mediated activation of the Qp would ensure expression
of EBNA1 that is essential formaintenance of the EBVgenome in
B cells. Results of our study strongly suggest that IL-21 is one of
the signals that could participate in this important process in vivo.
Strong induction of the Qp-initiated transcripts was detected in
IL-21-treated cultures of EBV+ B cells. However, binding of
STAT-containing complexes to the Qp promoter sequences was
not evident in EMSAs. This could suggest an alternative, STAT-
independent, mode of regulation of the Qp downstream of IL-21
receptor.
In summary, results from our study add to a growing body of
evidence that lymphoid tissue-produced signals such as CD40L,IL-2, IL-10, IL-6, IL-4, and IL-21, that direct normal B cell
development, could also control EBV life cycle by regulating
expression patterns of key EBV latent proteins in infected B
cells. EBV is an important pathogen because of its association
with several human B cell malignancies. Considering the
significant impact of different EBV proteins on lymphomagen-
esis, it is necessary to first understand how they are regulated
during latent infection in B cells in a healthy host. Discovery
that OCI-BCLs differentiated upon stimulation with IL-21 in a
manner similar to the primary human B cells (Ettinger et al.,
2005; Good et al., 2006; Konforte and Paige, 2006) validates
the use of this in vitro system in future studies of the
mechanisms that govern expression of oncogenes EBNA2 and
LMP1 in the context of B cell development, which may provide
novel insights for therapy of EBV-associated B cell lymphomas.
Materials and methods
Cell lines and culture conditions
Four EBV+ B cell lines (OCI-BCL1, OCI-BCL2, OCI-BCL3,
and OCI-BCL5) were established from EBV+ B cell populations
that initially grew in coculture with synovial fibroblasts isolated
from five arthritis patients (Konforte and Paige, 2006). Clonal
OCI-BCLs were established from cells seeded at one cell per
well. The protocol for informed consent and the use of human
tissues was approved by the Ethics Review Committees at the
Ontario Cancer Institute (OCI), University Health Network and
St.Michael's Hospital in Toronto, Canada. EBV− diffuse large B
cell lymphoma lines OCI-Ly19, OCI-Ly7, and EBV− multiple
myeloma line OCI-My2, were kindly provided by H. Messner
and K. Stewart labs (Ontario Cancer Institute, Toronto, Canada),
respectively. Blood-derived lymphoblastoid B cell line (LCL-
BRC) and tonsil-derived LCL (2D5-LCL) were kindly provided
by HM Dosch lab (The Hospital for Sick Children, Toronto),
where they were established by an in vitro infection with B95-8
strain of EBV. EBV+ Burkitt's lymphoma (BL) lines Raji and
Jijoye were obtained from the American Type Culture Collection
(ATCC) (Manassas, VA).
50 ng/ml of human recombinant IL-21 (Biosource) in IMDM
supplemented with penicillin, streptomycin, and 5% fetal calf
serum (FCS) was used for cell culture in all experiments. 2×105
cells were plated in 6-well plates on day 0. Cells were washed,
counted, and resuspended at 2×105 cells/well in the fresh
medium containing IL-21 every three or four days of sub-
sequent culture, unless indicated otherwise. Cell counts and
viability were determined by the exclusion of Trypan blue dye
by light microscopy.
For JAK inhibitor studies, cells were pretreated with 200 nM
of JAK inhibitor I (JAKi I) (Calbiochem) for 45 min at 37 °C
prior to addition of IL-21 to the cultures on day 0.
RNA isolation, cDNA synthesis, RT-PCR and Southern blotting
Cells were harvested, washed with PBS, and lysed with
RLT buffer (Qiagen) at 6×106 cells/600 μl RLT buffer, or
b2×106 cells/350 μl RLT buffer. Lysates were passed through
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RNeasy Mini kit according to the manufacturer's instructions
(Qiagen). 2 to 10 μg of total RNA (depending on the assay) was
transcribed to cDNA with SuperScript II Rnase H-reverse
transcriptase according to the manufacturer's instructions
(Invitrogen).
Primer sequences are as follows: ebna2: F-actttgagccacccaca-
gtaacca, R-tggagtgtctgacagttgttcctg, lmp1: F-tcctcctcttggcgctactg,
R-tcatcactgtgtcgttgtcc, lmp2a: F-atgactcatctcaacacata, R-catgt-
taggcaaattgcaaa, actin: F-atggccacggctgcttccagc, R-catggtggtgc-
cgccagacag. PCR conditions: ebna2, and lmp1: annealing
temperature=60 °C, 29 cycles; for lmp2a: annealing tempera-
ture=60 °C, 33 cycles; for actin: annealing temperature=60,
25 cycles.
Primer sequences and PCR conditions for amplification of
Cp-initiated polycistronic message, of Cp-, Qp-, ebna1 as well
as the probe design and the conditions for the Southern blotting
procedures were described previously (Tierney et al., 1994;
Zetterberg et al., 1999). For Cp-initiated transcripts: F-(C1/C2
exon splice): catctaaaccgactgaagaa, R-(W2 exon): ccctgaaggt-
gaaccgctta (PCR product: 240 bp); for Cp/Wp-initiated ebna1:
F-(Y3 exon): tggcgtgtgacgtggtgtaa, R-(K exon): catttccaggtc-
ctgtacct (PCR product: 265 bp); for Qp-initiated ebna1: F-
(Q exon): gtgcgctaccggatggcg, R-(K exon): catttccaggtcctgtacct
(PCR product: 238 bp), for L1-TR-initiated transcript: F: gcagat-
tacactgcgcttc, R-ccagagcatctccaataagtag (PCR product: 903 bp
from EBV genomic DNA, 749 bp from cDNA). PCR conditions:
Cp-initiated transcripts: annealing temperature=57 °C, 38 cycles;
Cp/Wp-initiated ebna1 and Qp-initiated ebna1: annealing tem-
perature=61 °C, 38 cycles; L1-TR-initiated transcripts: annealing
temperature=62 °C, 36 cycles).
For Southern blotting, PCR products representing a region of
Qp-initiated ebna1 and L1-TR were run on 1.2% agarose gel in
TAE buffer. DNAwas transferred to a nylon membrane (Hybond-
N) by a capillary flow in 0.2 M NaOH overnight and then UV
crosslinked. Labelling of the Qp probe (5'-agagagtagtctcagggcat-
3') and L1-TR probe (5'-ctctcaaggtcgtgttccatc-3') was done by
T4 polynucleotide kinase oligo 32P-labelling according to the
manufacturer's instructions (Invitrogen). The reaction was
terminated by the addition of 5 μl of 0.2 M EDTA (pH 8.0).
The probe was purified using Illustra ProbeQuant G-50 Micro
Columns (GE Healthcare).
Thy nylon membrane was pre-hybridized in hybridization
buffer for 2 h at 42 °C prior to addition of the labelled radio-
active probe. The probe was left to hybridize overnight. Fol-
lowing hybridization, the membrane was washed twice in 1×
SSC, 0.1% SDS for 20 min and once with 0.2× SSC, 0.1% SDS
for 15 min at 65 °C. The membrane was placed on a phos-
phoimager screen for 6 h before reading on a Phosphoimager
(Storm 860, Molecular Dynamics).
Protein analysis
Cell lines were incubated in IMDM supplemented with 5%
FCS with or without IL-21 (50 ng/ml) for 0, 20, 30, 60 min,
6.5 h, 24 h, 48 h, 72 h, and 6 days. 0.5–1×106 cells were then
collected and lysed in 20 μl of lysis buffer (1% NP40, 150 mMNaCl, 20 mM Tris pH 7.4, 5 mM NaF, 1 mM Na3VO4, 5 mM
Na4P2O7, 1 mM PMSF, 5 μg/ml aprotinin, 5 μg/ml leupeptin)
(Roche, Laval, PQ). Lysed cells were incubated on ice for
30 min and centrifuged at 14,000 ×rpm for 10 min at 4 °C to
remove the detergent insoluble fraction.
Nuclear lysates were prepared according to the following
protocol: cells were washed with PBS, and cell pellets were
resuspended in 0.4 ml of buffer A (10 mM HEPES; pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT,
0.5 mM PMSF). After 10 min on ice, 23 μl of 10% NP-40 was
added to the lysates. Nuclei were separated from cytosol by
centrifugation (13,000 ×g, 10 s) and were resuspended in 50 μl
of buffer B (20 mMHEPES; pH 7.9, 0.4 M NaCl, 1 mM EDTA,
1 mM EGTA, 0.1 mM PMSF). After 40 min on ice, lysates were
separated by centrifugation (13,000 ×g, 30 s), and supernatants
containing nuclear proteins were transferred to a new vial.
Protein concentration in the lysates was determined using the
Micro BCA™ protein assay reagent kit (Pierce, Rockford, IL)
according to the manufacturer's instructions. Lysates that were
adjusted to contain equal amounts of proteins were mixed with
4× NuPage™ sample buffer (Invitrogen/Helixx Technologies,
Inc). Protein samples were resolved on a 4–12% Bis–Tris
gradient gel (Invitrogen/Helixx Technologies, Inc) and trans-
ferred to a PVDF membrane in 20 mM Tris, 150 mM glycine,
20% methanol. Membranes were blocked in 5% milk/TBST
(TBS+0.3% Tween) for 2 h before probing with antibodies
against LMP1 (C1-4) (DAKO, Denmark) and actin (Cell
Signalling). Antibodies to c-Myc (Cell Signalling) and EBNA2
(PE2) (DAKO) were used to probe nuclear protein blots
overnight. Membranes were washed in TBST and probed with a
secondary antibody (goat anti-rabbit IgG or goat anti-mouse
IgG) conjugated to horse radish peroxidase (SIGMA) in 5%
milk/TBST. Enhanced chemiluminescence was performed
using ECL substrates (Amersham Pharmacia, Baie d'Urfe,
PQ) as described by the manufacturer.
Electrophoretic mobility shift assay (EMSA)
Cell lines were harvested when they reached the growth
density of 0.5×106 cell/ml. Nuclear lysis was performed
according to the following protocol: 30×106 cells were washed
with PBS, and cell pellets were resuspended in 1 ml of buffer
HB (12 mM HEPES;pH 7.9, 4 mM Tris; pH 7.9, 10 mM KCl,
0.6 mMEDTA, 5 mMMgCl2, 1 mMNa3VO4, 1 mMNaF, 1 mM
Na4P2O7, 0.6 mMDTT, 0.5mMPMSF, 10 µg/ml aprotinin, 2 µg/
ml leupeptin). After 1-min centrifugation (13,000 ×rpm) at 4 °C,
cells were resuspended in 700 µl of HB buffer and incubated on
ice for 30 min. During this time, cells were sheared with 26 1/2
gauge needle (used 1 cm3 syringe, sheared 20 times). Nuclei were
separated from cytosol by centrifugation (13,000 ×rpm, 40 s) and
were resuspended in 102 µl of HSB-KCl buffer (14 mMHEPES;
pH 7.9, 4.7 mM Tris; pH 7.9, 0.7 mM EDTA, 5.9 mM MgCl2,
1.2 mMNa3VO4, 1.2 mMNaF, 1.2 mMNa4P2O7, 0.7 mMDTT,
0.6 mM PMSF, 11.8 µg/ml aprotinin, 2.3 µg/ml leupeptin). 18 µl
of 2 M KCl was subsequently added to each reaction. After
40 min on ice, lysates were centrifuged (13,000 ×rpm, 20 m), and
supernatants containing nuclear proteinswere transferred to a new
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quantitation was further confirmed by running equal amount of
nuclear lysates on Western blots and probing for nuclear actin
expression. For binding reactions, equal amounts of nuclear
protein (20 μg/reaction) were incubated in 30 μl of total reaction
volume containing 5 mM HEPES pH 7.8, 5 mMMgCl2, 50 mM
KCl, 0.4mg/ml poly(dI–dC) and 10%glycerol for 10min at room
temperature. 32P-labelled double-stranded DNA probes were
added and the reaction was incubated for 15 min on ice. As
previously described the sequences of the sense strand of the
double-stranded DNA probes used are:
ED-L1 oligonucleotide probe (5'-agcttcgggtacagatttcccgaa-
agcggcggtg-3'), L1-TR probe (5'-agcttgggggccgcgcattcctggaaaaa-
gtggaggg-3') (Chen et al., 2001), L1-TR(mt): (5'-agcttgggggccgcg-
caggactcgtgaaagtggaggg-3'— with introduced mutations in bold
italics), and Qp probe (5'-agcttacgctttgcgaaaacgaaagtgctt-
gaaaaggcg-3')(Chen et al., 1999). STAT binding sites are under-
lined. The sequence of the sense strand of the double-stranded hSIE
DNA probe used is: (5'-agcttcatttcccgtaaatccct-3'). In some exper-
iments, excess of cold probe (1:100) or 2 μg of Abs against the
STAT1 (sc-464X; Santa Cruz, CA, USA) and STAT3 (Zymed) was
added to the reaction. The samples were loaded onto a 4.5%
polyacrylamide gel, and run for 3 h at 180 V. The gels were dried
and analyzed by autoradiography.
Immunohistochemistry
To visualize expression and cellular distribution of EBNA2
and LMP1 proteins, cytospins (105 cells/slide) were fixed in 2%
paraformaldehyde or acetone, respectively. Endogenous perox-
idase and biotin activities were blocked respectively using 3%
hydrogen peroxide and avidin/biotin blocking kit (Vector
Laboratories). Slides were then incubated at room temperature
with previously optimized monoclonal mouse anti-EBNA2
(1:30) (DAKO) or anti-LMP1 antibody (1:30) (DAKO). This
was followed by 30 min incubation each with biotinylated
secondary antibody (ID Labs Biotechnology Inc.) and horse-
radish peroxidase-conjugated ultrastreptavidin labelling reagent
(ID Labs Biotechnology Inc.). After washing in PBS, colour
development was done with freshly prepared NovaRed solution
(Vector Laboratories.). Finally, cytospins were counterstained
lightly with Mayer's hematoxylin, dehydrated in alcohols,
cleared in xylene and mounted in Permount (Fisher Scientific).
Cell images were visualized with Nikon OPTIPHOT upright
brightfield microscope using the objective lens by Olympus
Dplan 20×/0.4. The microscope was connected to CoolSNAP-
Procf colour camera (Roper Scientific Photometrics) and images
acquired with Media Cybernetics Image Pro PLUS software.
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